2023
Paths Forward for Clinicians Amidst the Rise of Unregulated Clinical Decision Support Software: Our Perspective on NarxCare
Buonora M, Axson S, Cohen S, Becker W. Paths Forward for Clinicians Amidst the Rise of Unregulated Clinical Decision Support Software: Our Perspective on NarxCare. Journal Of General Internal Medicine 2023, 39: 858-862. PMID: 37962733, PMCID: PMC11043299, DOI: 10.1007/s11606-023-08528-2.Peer-Reviewed Original ResearchClinical decision support toolClinical decision support softwareHealthcare institutionsOpioid prescribingOverdose epidemicPatient encountersIndividual cliniciansPatient careProprietary formulaRigorous external validationCliniciansWider implementationExternal validationPrescribingPotential harmSufficient evidencePublic healthDecision support softwareDecision support toolSpecific actionsMortalityCareCancer Screening for Transgender Individuals Guidelines, Best Practices, and a Proposed Care Model
Sterling J, Carbonella J, Jones T, Hanchuk S, Kelly P, Garcia M. Cancer Screening for Transgender Individuals Guidelines, Best Practices, and a Proposed Care Model. Urologic Clinics Of North America 2023, 50: 563-576. PMID: 37775215, DOI: 10.1016/j.ucl.2023.06.014.Peer-Reviewed Original ResearchConceptsTransgender patientsGender-affirming hormone therapyCancer screening recommendationsEvidence-based dataHigh-risk behaviorsHormone therapyScreening recommendationsCancer screeningCurrent guidelinesPractice patternsCare modelLong-term effectsCancer riskIndividual guidelinesPatientsSufficient evidenceCancerGuidelinesTherapyPrevention
2019
Surgical Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA Guideline Amendment 2019.
Foster H, Dahm P, Kohler TS, Lerner LB, Parsons JK, Wilt TJ, McVary K. Surgical Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA Guideline Amendment 2019. Journal Of Urology 2019, 202: 592-598. PMID: 31059668, DOI: 10.1097/ju.0000000000000319.Peer-Reviewed Original ResearchConceptsBenign prostatic hyperplasiaLUTS/benign prostatic hyperplasiaLower urinary tract symptomsUrinary tract symptomsTract symptomsSurgical managementProstatic hyperplasiaMale lower urinary tract symptomsEvidence-based surgical managementAssociated treatment algorithmFuture surgical optionsPre-operative testsInvasive surgical therapiesEvidence-based recommendationsQuality of lifeSufficient evidenceHealthcare of patientsLUTS increasesSurgical therapyConditional recommendationSurgical optionsTreatment algorithmCochrane LibraryBody of evidenceImportant diagnosis
2018
Castration-Resistant Prostate Cancer: AUA Guideline Amendment 2018
Lowrance W, Murad M, Oh W, Jarrard D, Resnick M, Cookson M. Castration-Resistant Prostate Cancer: AUA Guideline Amendment 2018. Journal Of Urology 2018, 200: 1264-1272. PMID: 30086276, DOI: 10.1016/j.juro.2018.07.090.Peer-Reviewed Original ResearchConceptsCastration-resistant prostate cancerNon-metastatic castration-resistant prostate cancerGuideline statementsIndividual patient's treatment goalsNewly-published literatureTreatment of patientsManagement of patientsPatient treatment goalsProstate cancerIndex patientPatientsTreatment goalsClinical practicePatient preferencesMeta-analysisShared decision-makingClinical principlesSystematic reviewPublished literatureSufficient evidenceGuidelinesReviewExpert opinionSystematic literature reviewCancer
2012
Biomarkers in idiopathic pulmonary fibrosis
Zhang Y, Kaminski N. Biomarkers in idiopathic pulmonary fibrosis. Current Opinion In Pulmonary Medicine 2012, 18: 441-446. PMID: 22847105, PMCID: PMC4165635, DOI: 10.1097/mcp.0b013e328356d03c.Peer-Reviewed Original ResearchConceptsIdiopathic pulmonary fibrosisPeripheral blood biomarkersPulmonary fibrosisBlood biomarkersDisease presenceMultiple clinical contextsPeripheral bloodPredictive biomarkersGene polymorphismsLarger studyDrug studiesOutcome trajectoriesPrediction ruleClinical contextBiomarkersMolecular biomarkersMultiple studiesPatientsFibrosisSufficient evidenceOutcomesProtein markersConvincing evidenceRecent studiesMarkers
2007
Exercise and Quality of Life Outcomes in Patients With Cancer
Knobf MT, Musanti R, Dorward J. Exercise and Quality of Life Outcomes in Patients With Cancer. Seminars In Oncology Nursing 2007, 23: 285-296. PMID: 18022056, DOI: 10.1016/j.soncn.2007.08.007.Peer-Reviewed Original ResearchConceptsPhysical functioningHealth conditionsPhysical activity recommendationsRelationship of exercisePatients' physical functioningIndividual health conditionsExercise interventionMuscle strengthPhysical functionMutual goal settingActivity recommendationsNursing practiceLife outcomesSocial functioningSelf-esteemLife domainsGoal settingPatientsSufficient evidenceExerciseCancerInterventionMore researchFunctioningLiterature review
2006
Skin Exposure to Isocyanates: Reasons for Concern
Bello D, Herrick CA, Smith TJ, Woskie SR, Streicher RP, Cullen MR, Liu Y, Redlich CA. Skin Exposure to Isocyanates: Reasons for Concern. Environmental Health Perspectives 2006, 115: 328-335. PMID: 17431479, PMCID: PMC1849909, DOI: 10.1289/ehp.9557.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsSkin exposureIsocyanate asthmaSuch exposureAsthma-like responsesSubsequent inhalation challengeOccupational SafetyPersonal protective equipmentInhalation challengeOccupational asthmaSystemic sensitizationAsthmaInhalation exposureHealth AdministrationComputerized searchRespiratory exposureRelevant articlesProtective equipmentHuman literatureSkin absorptionSensitizationGoogle databasesNational InstituteLines of evidencePotential roleSufficient evidence
2005
Mental stress ischemia: Present status and future goals
Burg MM, Vashist A, Soufer R. Mental stress ischemia: Present status and future goals. Journal Of Nuclear Cardiology 2005, 12: 523-529. PMID: 16171711, DOI: 10.1016/j.nuclcard.2005.06.085.Peer-Reviewed Original ResearchConceptsEvent-free survival rateLarge-scale clinical trialsAssessment of prognosisForms of ischemiaComplex clinical manifestationsSubstantial clinical impactClinical manifestationsPrognostic significanceClinical trialsClinical impactSurvival rateDiagnostic standardizationTreatment effectsIschemiaNuclear cardiologyPrognosisPathophysiologySufficient evidenceAdditional modalitiesTrialsFurther testingTreatmentPrevalenceCardiology
1981
Dermo‐distortive urticaria: An autosomal dominant dermatologic disorder
Epstein P, Kidd K, Opitz J. Dermo‐distortive urticaria: An autosomal dominant dermatologic disorder. American Journal Of Medical Genetics 1981, 9: 307-315. PMID: 7294069, DOI: 10.1002/ajmg.1320090407.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply